minocycline and pazufloxacin

minocycline has been researched along with pazufloxacin* in 2 studies

Other Studies

2 other study(ies) available for minocycline and pazufloxacin

Article	Year
Successful Additional Corticosteroid Treatment in a Patient with Mycoplasma pneumoniae Pneumonia in whom a Monobacterial Infection was Confirmed by a Molecular Method Using Bronchoalveolar Lavage Fluid. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6 A 23-year-old Japanese woman was admitted to A hospital due to pneumonia. IgM for Mycoplasma pneumoniae was positive, and the patient was treated with imipenem/cilastatin, clindamycin, pazufloxacin and minocycline. However, both the chest radiological findings and the symptoms became exacerbated, and she was therefore transferred to our hospital. The bronchoalveolar lavage fluid was obtained, and a 16S rRNA gene sequencing analysis revealed a monobacterial infection of Mycoplasma pneumoniae. Therefore, corticosteroid treatment in addition to minocycline was administered, and the patients symptoms, laboratory data and chest radiographs improved. Corticosteroid therapy may therefore be considered for patients with refractory M. pneumoniae pneumonia. Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cilastatin; Cilastatin, Imipenem Drug Combination; Clindamycin; Disease Progression; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Minocycline; Mycoplasma pneumoniae; Oxazines; Pneumonia, Mycoplasma; Radiography, Thoracic; RNA, Ribosomal, 16S; Treatment Outcome	2016
[Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)]. The Japanese journal of antibiotics, 2005, Volume: 58, Issue:1 The in vitro combination effects of pazufloxacin (PZFX) with an anti-MRSA drug such as vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), minocycline (MINO), rifampicin (RFP) and sulfamethoxazole-trimethoprim (ST) were investigated against 26 strains of beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR) by the checkerboard method. The additive and synergistic effects were observed with the combination of PZFX and VCM (50%, 13/26 strains), PZFX and TEIC (96%, 25/26 strains), PZFX and ABK (65%, 17/26 strains), PZFX and MINO (46%, 12/26 strains), PZFX and ST (54%, 14/26 strains). The synergistic effects were observed with the combination of PZFX and TEIC (4%, 1/26 strains), PZFX and ABK or MINO (15%, 4/26 strains). The antagonistic effects were observed with only PZFX and MINO (12%, 3/26 strains), others were all indifference. Topics: Aminoglycosides; beta-Lactams; Dibekacin; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; In Vitro Techniques; Methicillin Resistance; Minocycline; Oxazines; Staphylococcus aureus; Teicoplanin; Vancomycin Resistance	2005

Article

Year

Successful Additional Corticosteroid Treatment in a Patient with Mycoplasma pneumoniae Pneumonia in whom a Monobacterial Infection was Confirmed by a Molecular Method Using Bronchoalveolar Lavage Fluid.

Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6

A 23-year-old Japanese woman was admitted to A hospital due to pneumonia. IgM for Mycoplasma pneumoniae was positive, and the patient was treated with imipenem/cilastatin, clindamycin, pazufloxacin and minocycline. However, both the chest radiological findings and the symptoms became exacerbated, and she was therefore transferred to our hospital. The bronchoalveolar lavage fluid was obtained, and a 16S rRNA gene sequencing analysis revealed a monobacterial infection of Mycoplasma pneumoniae. Therefore, corticosteroid treatment in addition to minocycline was administered, and the patients symptoms, laboratory data and chest radiographs improved. Corticosteroid therapy may therefore be considered for patients with refractory M. pneumoniae pneumonia.

Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cilastatin; Cilastatin, Imipenem Drug Combination; Clindamycin; Disease Progression; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Minocycline; Mycoplasma pneumoniae; Oxazines; Pneumonia, Mycoplasma; Radiography, Thoracic; RNA, Ribosomal, 16S; Treatment Outcome

2016

[Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)].

The Japanese journal of antibiotics, 2005, Volume: 58, Issue:1

The in vitro combination effects of pazufloxacin (PZFX) with an anti-MRSA drug such as vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), minocycline (MINO), rifampicin (RFP) and sulfamethoxazole-trimethoprim (ST) were investigated against 26 strains of beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR) by the checkerboard method. The additive and synergistic effects were observed with the combination of PZFX and VCM (50%, 13/26 strains), PZFX and TEIC (96%, 25/26 strains), PZFX and ABK (65%, 17/26 strains), PZFX and MINO (46%, 12/26 strains), PZFX and ST (54%, 14/26 strains). The synergistic effects were observed with the combination of PZFX and TEIC (4%, 1/26 strains), PZFX and ABK or MINO (15%, 4/26 strains). The antagonistic effects were observed with only PZFX and MINO (12%, 3/26 strains), others were all indifference.

Topics: Aminoglycosides; beta-Lactams; Dibekacin; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; In Vitro Techniques; Methicillin Resistance; Minocycline; Oxazines; Staphylococcus aureus; Teicoplanin; Vancomycin Resistance

2005